Can Trevi Therapeutics (TRVI) Stock Reach $29?

Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. With no commercial revenue yet, its valuation is driven almost entirely by clinical pipeline momentum and the probability that late-stage trials succeed. That makes the question of a $29 stock price target a question about science, cash, and time as much as about valuation.

Key Takeaways

• The central target of $29 is the arithmetic mean of nine verified, current analyst price targets (rounded from roughly $28.89), not an official published consensus.
• The latest verified price is $11.90, meaning the stock would need to rise about 144% to reach $29 — a very large move.
• Individual targets span a wide range, from $23 to $40, reflecting genuine disagreement about how far the Haduvio pipeline can re-rate the shares.
• Coverage is unanimously bullish — all nine firms rate TRVI a Buy — yet the spread of targets signals elevated uncertainty.
• The strongest supports are late-stage clinical programs and a cash runway that management says extends into 2029; the biggest risk is binary trial failure in a company with no product revenue.

Analyst Price Targets and Consensus View

Nine current analyst targets were reviewed to establish the central figure. The approximate low-to-high range is $23 to $40. Targets include BMO Capital at $36, Raymond James at $40, B. Riley Securities at $31 (initiated August 2026), Cantor Fitzgerald at $30, JonesTrading at $28, Oppenheimer at $25, H.C. Wainwright at $24, and Morgan Stanley and Needham each at $23. The mean of these nine values is about $28.89, which rounds to a $29 central target. For context, S&P Global reports an average near $28 across a slightly larger set of analysts, underscoring that this is not an official published consensus but a calculated figure.

Every firm carries a Buy or equivalent rating, so the disagreement is not about direction but magnitude. Bullish analysts emphasize the large chronic-cough market opportunity and positive Phase 2 data; more cautious analysts weigh the risk that Phase 3 trials have yet to read out and that TRVI remains pre-revenue. Several firms raised targets in mid-2026, including Cantor Fitzgerald (to $30), JonesTrading (to $28), and B. Riley (new $31), a sign that sentiment has been improving on the back of trial progress.

Current Market Position and Path Toward the Target

With the latest verified close at $11.90, reaching $29 implies roughly 144% upside — a very large move by any standard. The stock sits well below its 52-week high of $20.22 reached in July 2026 and has pulled back more than 40% from that peak, trading below both its 50-day and 200-day moving averages. Market capitalization is roughly $1.7 billion, with about 142.5 million shares outstanding and short interest near 10% of the float.

A move toward the target would most plausibly be driven by catalysts rather than fundamentals: positive Phase 2b data, favorable sample-size re-estimation (SSRE) results for the RCC program, or steady enrollment progress in the two Phase 3 IPF trials. Because the company reports losses and no meaningful revenue, conventional earnings-based valuation does not yet anchor the price; the path is defined by derisking the pipeline.

What Could Support a Move Toward the Target

• Late-stage pipeline breadth. Haduvio is being tested across IPF-related chronic cough, RCC, and non-IPF interstitial lung disease (ILD) cough, expanding the addressable patient population.
• Positive prior data. The Phase 2b CORAL trial results were published in JAMA and featured at the 2026 American Thoracic Society meeting, supporting confidence in the mechanism.
• Cash runway. A $150 million offering completed in April 2026, together with existing resources, is expected to fund operations into 2029, reducing near-term dilution overhang.
• Rising analyst targets. Multiple firms lifted price targets through mid-2026 as trial execution progressed, a tailwind for sentiment.

What Could Prevent the Target From Being Reached

• Clinical trial risk. Phase 3 results for the IPF cough program are not expected until late 2027 and the first half of 2028, leaving a long window of binary uncertainty.
• No revenue. As a pre-commercial company, TRVI relies on capital markets and partnerships; any setback can trigger sharp valuation compression.
• Dilution. Share count has risen substantially over the past year, and future financings could weigh on per-share value.
• Competition and execution. Chronic-cough indications are contested, and enrollment or regulatory delays could push timelines out.

Technical Levels and Market Structure

The 52-week low near $9.82 is the most important support level; a sustained break below it would mark a new downtrend. On the upside, the $14–$15 zone — where the 200-day and 50-day moving averages and prior consolidation sit — represents the first meaningful resistance. The stock's relative strength index (RSI) has fallen into oversold territory near 20, which can precede short-term bounces but does not by itself signal a durable bottom. The gap between $11.90 and $29 means the technical path would require re-establishing an uptrend through multiple prior levels before any fundamental re-rating completes.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month horizon, though for a clinical-stage name with Phase 3 readouts in 2027–2028, some targets implicitly look further out. Investors should monitor the next earnings report (estimated for mid-November 2026), the SSRE results for the RCC LAKE trial expected in the fourth quarter of 2026, enrollment milestones for the OCEAN Phase 3 trials, and any regulatory feedback on the non-IPF ILD program. Changes in analyst targets, share-count increases, and sector appetite for unprofitable biotech will also shape the path.

AI Daily Buy/Sell Signals

For traders tracking a volatile, catalyst-driven name like TRVI, AI Daily Buy/Sell Signals from Tickeron offer a systematic way to monitor shifting conditions. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual review allows. Explore the AI Daily Buy/Sell Signals to see how automated monitoring can support your decision-making process.

Final Assessment

The $29 central target — the mean of nine verified analyst targets spanning $23 to $40 — sits about 144% above the latest price of $11.90, making it a very large required move. The bullish case rests on a broadening Haduvio pipeline, positive Phase 2 data, and funding into 2029; the bearish case rests on a pre-revenue model, a long wait for Phase 3 readouts, and the possibility of dilution or clinical failure. The wide analyst range and the stock's recent drawdown from its 52-week high both signal genuine uncertainty. Whether TRVI reaches $29 will depend primarily on clinical execution and trial results rather than near-term earnings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations